GALWAY, Ireland--(BUSINESS WIRE)-- Cappella, Inc. (Cappella) announced today that it has completed the second tranche of a €10.5 million Series D investment. The round includes several new investors, including private investor, KfW, as well as growth financing from Kreos Capital Limited and Silicon Valley Bank.
Cappella has initiated commercial activities of its Sideguard stent system in over 12 countries in Europe, South America, the Middle East and Asia. “The Sideguard® system is uniquely designed to protect the ostial sidebranch anatomy and provides the interventional cardiologist with a safe and easy-to-use product for the preservation of sidebranch patency. The Sideguard system is available in a wide variety of sizes, and combines both the unique features of self expanding nitinol stent technology with the proprietary balloon activated delivery system for precise placement,” said Michael Gilmore, Vice President of R&D and Regulatory Affairs for Cappella.
“The company is developing an expanded pipeline of Sideguard system products to exploit its unique stent and delivery system technologies allowing us to address additional applications. These new Sideguard products will enable us to address virtually all significant sidebranch lesions and complex ostial anatomies. With this broader range of products, we see upside to our initial market projections,” commented Dr. Art Rosenthal, CEO of Cappella.
In addition, Eamon Hobbs, Chairman of the Board added, ““We are delighted to experience the support of our investors and a deepening and growing interest for the use of our device.”
About Cappella
Cappella, Inc. is a medical device company that develops novel solutions for the treatment of complex coronary artery disease (CAD) focused on protecting the coronary sidebranch arteries. Cappella’s Sideguard® coronary sidebranch technology offers interventional cardiologists a straightforward, effective, and easy to use solution that preserves the sidebranch of diseased coronary arteries by protecting the ostium while minimizing plaque shift. The Sideguard delivery system features a proprietary split-sheath, balloon released, technology that ensures precise placement on the ostial borderline. The Sideguard self-expanding, nitinol, stent promotes continuous wall apposition and positive remodeling and its unique trumpet-shaped design conforms to varying characteristics of the sidebranch ostium. Cappella Medical Devices Ltd., Galway, Ireland is the R&D and manufacturing subsidiary of Cappella, Inc. For more information, please visit the Cappella Medical Systems website at www.cappella-med.com.
Contact:
Cappella Medical Devices Limited Phil Watson, +353 (0) 91 758 939 pwatson@cappella.ie
